Trial(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Trial details
- Registry ID
- NCT04996875
- Phase
- Phase 2
COGT
Cogent Biosciences, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
3Trials in this database
9Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| (Apex) Bezuclastinib in Patients With Advanced Systemic MastocytosisNCT04996875 | COGT | Phase 2 | Recruiting | 2025-09-19Actual |
| (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic MastocytosisNCT05186753 | COGT | Phase 2 | Active not recruiting | 2025-05-22Actual |
| (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal TumorsNCT05208047 | COGT | Phase 3 | Recruiting | 2025-09-30Actual |
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Trial details
- Registry ID
- NCT05186753
- Phase
- Phase 2
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Trial details
- Registry ID
- NCT05208047
- Phase
- Phase 3
Latest recorded trial changes
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
NCT05208047 · Cogent Biosciences, Inc.
Recruitment status changed
− Before
Active not recruiting
+ After
Recruiting
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
NCT05208047 · Cogent Biosciences, Inc.
Planned enrollment increased by 40 participants
− Before
442 participants (planned)
+ After
482 participants (planned)
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
NCT04996875 · Cogent Biosciences, Inc.
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
Sep 2025
+ After
19 Sep 2025
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
NCT05208047 · Cogent Biosciences, Inc.
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
Jul 2025
+ After
30 Sep 2025
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
NCT05186753 · Cogent Biosciences, Inc.
Planned enrollment increased by 30 participants
− Before
207 participants (planned)
+ After
237 participants (planned)
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
Sep 2025
+ After
22 May 2025